These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 11138684)

  • 1. FDG PET in thyroid cancer: thyroxine or not?
    Grünwald F; Biersack HJ
    J Nucl Med; 2000 Dec; 41(12):1996-8. PubMed ID: 11138684
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
    Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
    J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of FDG PET in differentiated thyroid cancer.
    Macapinlac HA
    J Nucl Med; 2001 Jan; 42(1):77-8. PubMed ID: 11197984
    [No Abstract]   [Full Text] [Related]  

  • 4. Changing paradigms in the follow-up of patients with differentiated thyroid cancer: an alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning.
    Mazzaferri EL
    Endocr Pract; 2003; 9(4):324-6. PubMed ID: 14561580
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of 18F-FDG PET/CT in thyroid carcinoma.
    Muros de Fuentes MA; Mitjavila Casanovas M; Estorch Cabrera M; Lecumberri Santamaria B; Navarro González E
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):186-92. PubMed ID: 26944558
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased F-18 fluorodeoxyglucose accumulation in a benign neurofibroma--a pitfall in a patient with thyroid cancer: a case report.
    Gabriel M; Erler H; Donnemiller E; Riccabona G
    Nuklearmedizin; 2002 Apr; 41(2):N14-5. PubMed ID: 11989305
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of FDG PET in metastatic thyroid cancer.
    Wong CO; Dworkin HJ
    J Nucl Med; 1999 Jun; 40(6):993-4. PubMed ID: 10452316
    [No Abstract]   [Full Text] [Related]  

  • 8. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343
    [No Abstract]   [Full Text] [Related]  

  • 10. [F-18-FDG PET in autonomous goiter].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1999; 38(1):1-6. PubMed ID: 9987775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rapid diagnosis of recurrence of a tall cell variant of papillary thyroid cancer by endogenous TSH stimulation].
    Görges R; Liedke MO; Worm K; Frilling A; Bockisch A; Schmid KW
    Nuklearmedizin; 2003 Jun; 42(3):N15-8. PubMed ID: 12848153
    [No Abstract]   [Full Text] [Related]  

  • 13. Vocal cord muscle activity as a drawback to FDG-PET in the followup of differentiated thyroid cancer.
    Igerc I; Kumnig G; Heinisch M; Kresnik E; Mikosch P; Gallowitsch HJ; Gasser J; Haselbach H; Lind P
    Thyroid; 2002 Jan; 12(1):87-9. PubMed ID: 11838737
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of F-18FDG PET in thyroid cancer.
    Lind P; Kumnig G; Matschnig S; Heinisch M; Gallowitsch HJ; Mikosch P; Kresnik E; Gomez I; Unterweger O
    Acta Med Austriaca; 2000; 27(2):38-41. PubMed ID: 10812462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer.
    Feine U
    Eur J Endocrinol; 1998 May; 138(5):492-6. PubMed ID: 9625358
    [No Abstract]   [Full Text] [Related]  

  • 16. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
    Wang W; Larson SM; Fazzari M; Tickoo SK; Kolbert K; Sgouros G; Yeung H; Macapinlac H; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1107-13. PubMed ID: 10720047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
    Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
    J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.